ArticleLeukemia2023

Preclinical development of 1B7/CD3, a novel anti-TSLPR bispecific antibody that targets CRLF2-rearranged Ph-like B-ALL.

Ze Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.